Form 4: Capricor Therapeutics CEO Linda Marban Acquires Stock Options
SEC Form 4 Filing
Capricor Therapeutics CEO Linda Marban was granted stock options for 244,962 shares on January 2, 2025, according to a recent SEC filing.
Summary
- Linda Marban, CEO of Capricor Therapeutics, was granted stock options on January 2, 2025.
- The options are for a total of 244,962 shares of common stock.
- One grant of 210,000 options vests monthly starting February 1, 2025, over 48 months.
- The other grant of 34,962 options is fully vested and exercisable immediately.
- The exercise price for both grants is $14.96 per share.
- The options expire on January 2, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The grant of stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule for the larger grant encourages long-term commitment from the CEO.
- The immediate vesting of a portion of the options provides an immediate incentive.
Risks
- The CEO could potentially leave the company before the options fully vest, which could impact the company's leadership.
- The early exercise feature of the options could lead to restricted stock if the CEO leaves before vesting.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of 48 months is typical for such grants.
- The exercise price is set at a specific value, which is common practice.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of stock option grant. |
| 01/06/2025 | Date of SEC filing. |
| 02/01/2025 | Start date for monthly vesting of 210,000 stock options. |
| 01/02/2035 | Expiration date of the stock options. |
Keywords
stock options, insider trading, executive compensation, SEC filing, Capricor Therapeutics, Linda Marban, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.